GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
about
GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.Effects of a brown beans evening meal on metabolic risk markers and appetite regulating hormones at a subsequent standardized breakfast: a randomized cross-over study.Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cellsGender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experienceCentral control of body weight and appetite.Current therapeutic strategies in non-alcoholic fatty liver disease.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.Experimental diabetes treated with trigonelline: effect on key enzymes related to diabetes and hypertension, β-cell and liver function.[Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)].
P2860
Q33745485-6F4950F5-7C79-45E9-ACFD-CBEBB50FFEBAQ33927198-FE77B74D-9F51-4B6A-AFEE-B67F7EBB8FA8Q34410733-3D0989DD-7AAD-4018-9D05-E544248B2423Q34663627-9CAD7359-27E2-4832-9EE5-A6711C9D0851Q35108666-33319C75-73E9-4E65-92E2-6D8DFFEF2D0FQ36766081-8516164B-EE70-4A89-9030-3BB59B260578Q36979763-56A5B01A-BA74-4081-A9F9-59A73F658BBBQ37859419-F5E28743-19CF-4EE4-8118-F195DBF193A1Q38866310-D4C53E07-0696-433C-B640-7DCF118BDAD4Q39193265-470B4884-4236-474A-9E58-905DF09E6669Q39376180-99F99F34-89C0-45E9-AD64-8F933A2B88C8Q50919355-DA1B995E-78DA-4DA8-8E59-4E0D1170C647Q53807699-09D40796-743D-4299-9169-F17A5914DA9F
P2860
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@en
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@nl
type
label
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@en
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@nl
prefLabel
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@en
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@nl
P1476
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
@en
P2093
P2888
P304
P356
10.1007/S11892-007-0056-9
P577
2007-10-01T00:00:00Z